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ABSTRACT
Protein-based methods of siRNA delivery are capa-
ble of uniquely specific targeting, but are limited by
technical challenges such as low potency or poor
biophysical properties. Here, we engineered a series
of ultra-high affinity siRNA binders based on the vi-
ral protein p19 and developed them into siRNA car-
riers targeted to the epidermal growth factor recep-
tor (EGFR). Combined in trans with a previously de-
scribed endosome-disrupting agent composed of the
pore-forming protein Perfringolysin O (PFO), potent
silencing was achieved in vitro with no detectable cy-
totoxicity. Despite concerns that excessively strong
siRNA binding could prevent the discharge of siRNA
from its carrier, higher affinity continually led to
stronger silencing. We found that this improvement
was due to both increased uptake of siRNA into the
cell and improved pharmacodynamics inside the cell.
Mathematical modeling predicted the existence of
an affinity optimum that maximizes silencing, after
which siRNA sequestration decreases potency. Our
study characterizing the affinity dependence of si-
lencing suggests that siRNA-carrier affinity can sig-
nificantly affect the intracellular fate of siRNA and
may serve as a handle for improving the efficiency
of delivery. The two-agent delivery system presented
here possesses notable biophysical properties and
potency, and provide a platform for the cytosolic de-
livery of nucleic acids.
INTRODUCTION
Protein-based systems for delivering siRNA can potentially
circumvent some of the challenges facing nanoparticle-
based systems, such as accumulation in the liver (1,2). Al-
though there exists multiple examples of protein-based de-
livery methods (3–7), they generally suffer from low poten-
cies, complex preparation strategies, or poor pharmacoki-
netics and biodistribution properties stemming from high
positive charge (8,9). Hence, multiple technical barriers still
need to be overcome for protein-based methods to become
a competitive delivery strategy.
Proteinaceous delivery vehicles commonly require both a
carrier functionality, provided by amoiety that is chemically
conjugated to or non-covalently complexed with siRNA,
and an endosomal release functionality, which can be ex-
plicitly defined or embedded within the vehicle. For exam-
ple, Dowdy et al. used the double-stranded RNA binding
domain (dsRBD) of Protein Kinase R (PKR) fused with
protein transduction domains (PTDs) to respectively bind
and transport siRNA across the cell membrane (6,10).
Previously, we reported amulti-agent delivery system that
also employed the dsRBD of PKR as a siRNA carrier.
Administered together with an endosome-disrupting agent
based on the pore-forming protein Perfringolysin O (PFO),
and a receptor-clustering antibody that enhances siRNA
uptake, efficient silencing was achieved in vitro (11). While
the non-cationic and non-particulate nature of this deliv-
ery system suggested that desirable pharmacokinetics and
biodistribution properties could be achieved in vivo, we ob-
served that siRNAdissociated rapidly from the dsRBDdur-
ing circulation, negating the targeting functionalities of the
carrier protein.
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To address this delivery limitation, we focused on devel-
oping siRNA carriers with higher affinities for siRNA. To
this end, we chose the p19 protein of the Carnatian Ital-
ian Ringspot Virus (CIRV) as an alternative siRNA-binding
scaffold. Like dsRBDs, p19 binds specifically to double-
stranded RNA (dsRNA) independent of sequence, and not
to single-stranded RNA (ssRNA) or DNA (12). However,
in contrast to dsRBDs, p19 binds in a size-dependent man-
ner to dsRNAs the length of siRNA, providing increased
specificity (12,13). Importantly, p19 has a naturally higher
affinity for siRNA (13,14), which provides an excellent
backbone to further engineer ultra-high affinity siRNA car-
riers.
Although our prior work indicated that siRNA carri-
ers with higher affinity would be required for successful
in vivo targeting, strong binding can also come with po-
tential drawbacks. Indeed, previous observations have sup-
ported the notion that excessively strong binding between
siRNA and its delivery vehicle is undesirable, as it may pre-
vent siRNA from being released and subsequently loaded
onto the RNA-induced silencing complex (RISC) (15,16).
For example, Schroeder et al. observed that stronger bind-
ing between siRNA and various PEI–lipid conjugates cor-
related with decreased silencing potency (15). Han et al. ob-
served that continually increasing the polymer-siRNAbind-
ing strength eventually caused a decline in silencing potency
(16). Despite such precedents, we reasoned that our deliv-
ery system is distinct from the previously reported formula-
tions in that our siRNA carrier is physically separate from
the endosome-disrupting agent. Thismodularity gave us the
opportunity to isolate siRNA-carrier affinity as a true inde-
pendent variable for characterizing its influence on silencing
potency.
Here, we report the engineering of ultra-high affinity
siRNA binding proteins based on the p19 scaffold and their
development into targeted siRNA carriers. Combined with
the PFO-based endosome-disrupting agent (17), potent si-
lencing was achieved in vitro with no signs of cytotoxicity.
Unexpectedly, higher carrier affinity continually increased
the silencing potency even when there were no additional
gains in siRNA uptake, suggesting that higher affinity also
allowed for more efficient delivery to RISC downstream of
siRNA internalization. Mathematical modeling predicted
that this positive correlation between affinity and potency
will eventually reverse, indicating the existence of an affinity
optimum that maximizes silencing. In this study, a 20-fold
improvement in potency was achieved by increasing affinity
alone, suggesting that tuning siRNAaffinitymay provide an
additional avenue for increasing the efficiency of delivery.
Overall, our results imply that siRNA-carrier affinity may
significantly influence the intracellular pharmacodynamics
of siRNA, beyond its previously assigned roles in affect-
ing particle stability and cellular uptake. Furthermore, the
ultra-high affinity siRNA binders developed for this study
may serve as useful tools for diverse applications involving
dsRNA detection, isolation or sequestration.
MATERIALS AND METHODS
Cell lines
A431 cells (ATCC) and A431 cells stably transfected with
destabilized EGFP (A431-d2EGFP) (11) were cultured in
DMEM (ATCC) supplemented with 10% heat-inactivated
FBS (Life Technologies). The A431-d2EGFP cells received
0.1 mg/mL G418 (Corning) in addition. All cell lines were
maintained at 37◦C and 5% CO2 in a humidified incubator.
siRNA
Please refer to Supplementary Table S1 for sequences, mod-
ifications and vendor information.
Affinity maturation of p19
Affinity maturation of p19 was performed using standard
yeast surface display techniques as previously described (18)
with select modifications. P19 was mutagenized by error-
prone PCR and displayed on the surface of yeast fused
to human Fc (IgG1). The resulting library was screened
by fluorescence activated cell sorting (FACS) following ki-
netic sorting methods (19) where clones are selected for a
slower dissociation rate. Three siRNAs were used for selec-
tion (Seq F, Seq I and Cy5-labeled AllStars negative control
siRNA). Dissociation was performed in PBSA containing
55% mouse serum (EMD Millipore) at 37◦C to mimic in
vivo conditions. Unlabeled siRNA (unmodified Seq F) was
added at a 100-fold molar excess over the estimated con-
centration of labeled siRNA. The final concentration of the
competitor was between 1.7 and 2.5 M. Six rounds of se-
lections were performed in total, cycling between the dif-
ferent siRNAs twice to prevent specific binding to any one
sequence. The competition time was increased from 15min-
utes in the first selection cycle to 1 hour in the second cycle.
Plasmids were isolated and sequenced from the enriched li-
brary as previously described (18).
Protein expression and purification
The PFO-based endosome-disrupting agent
(C225.2/PFOT490A,L491V) was prepared as previously
described (17). The p19, p19-E6, p19-E18 clones and
SUMO-E18 were expressed from the pE-SUMO vec-
tor (LifeSensors) in Rosetta 2 (DE3) Escherichia coli
(Novagen) and purified by Talon metal affinity chromatog-
raphy (Clontech) following previously described methods
(17). Following cleavage of the SUMO tag, the p19 con-
structs were purified by anion exchange chromatography
(AEX) and size-exclusion chromatography (SEC). AEX
was performed using a HiTrap Q HP anion exchange
column (GE Healthcare Life Sciences) with an increasing
salt gradient (10–500 mM NaCl) in 20 mM Bis–Tris, pH
6.5. SEC was performed using a HiLoad 16/600 Superdex
75 pg column (GE Healthcare Life Sciences) in PBS.
Analytical SEC was performed using a Superdex 75 10/300
GL column (GE Healthcare Life Sciences) or Superdex
200 Increase 10/300 GL column (GE Healthcare Life
Sciences) in PBS. Detailed methods for the expression
and purification of p19 are provided in Supplementary
Methods.
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Dynamic light scattering
Targeted p19 constructs were analyzed at 5 M (dimer con-
centration) in PBS (pH 7.4), either alone or complexed with
siRNA (unmodified Seq F) at a molar ratio of 1:1 (p19
dimer: siRNA). For complexation, p19 and siRNA were
incubated for 30 minutes at 4◦C or on ice. Samples (50 l
each) were equilibrated to 25◦C and analyzed with the Dy-
naPro NanoStar Light Scatterer (Wyatt Technology) using
the Dynamics software (Wyatt Technology). Each run con-
sisted of 20 acquisitions (10 s per acquisition), and two runs
were performed per sample.
Biolayer interferometry (BLI)
All measurements were performed in citrate-phosphate
buffer containing 100 mM NaCl, 0.1% BSA and 0.002%
Tween-20 at 37◦C using an Octet RED96 instrument
(Pall ForteBio LLC). Biotinylated hFc-EGFR (prepared
in-house (20)) or biotinylated siRNA (Seq 7) was cap-
tured on streptavidin-coated BLI tips (Pall ForteBio). P19-
E6/siRNA and p19-E18/siRNA complexes were prepared
by incubating the carriers and siRNA (unmodified Seq F)
at a 1:1 molar ratio (p19 dimer: siRNA) for 30 min at 4◦C
immediately prior to BLI. Association was analyzed at var-
ious concentrations of the p19 constructs (2-fold dilutions
from 10 to 0.16 nM for EGFRaffinitymeasurements; 2-fold
dilutions from 25 to 0.78 nM for siRNA affinity measure-
ments with untargeted p19; 2-fold dilutions from 10 to 0.31
nM for siRNA affinity measurements with the untargeted
p19 mutants). Dissociation was performed for between 30
min and 1 h. The buffer baseline from loaded tips was sub-
tracted from the data, which were then globally fitted to a
1:1 binding model to obtain apparent affinities.
MSD-SET
MSD-SETwas performed as previously described (21) with
minor modifications. Briefly, standard bind plates (Meso
Scale Discovery) were coated with 100 nM of each p19
clone in PBS for 30 min at room temperature or overnight
at 4◦C, then blocked and washed. Samples were prepared
by incubating 100 pM of biotinylated siRNA (Seq 7) with
varying concentrations of each p19 clone (3-fold serial di-
lutions from 200 nM to 2 pM) in PBS, 0.1% BSA for 24 h
at room temperature. Samples were then applied to plates
coated with the respective p19 clone for 150 s with shak-
ing to capture any free siRNA. Captured siRNA was de-
tected with sulfotag-labeled streptavidin (Meso Scale Dis-
covery) imaged on a MSD Sector Imager 2400 instrument
(Meso Scale Discovery). The collected data was fitted to a
quadratic equilibrium binding model (22) to obtain dissoci-
ation constants. Liquid handling was performed robotically
to minimize variability.
GFP silencing assays
A431 or A431-d2EGFP cells were seeded at a density of
15 000 cells/well in 96-well plates 16–20 h prior to the ex-
periment. The p19 constructs were incubated with nega-
tive control siRNA (Qiagen) or GFP siRNA (GE Dhar-
macon) at a 1:1 molar ratio (p19 dimer: siRNA) for 30
min at 4◦C or on ice. The p19/siRNA complexes were
then serially diluted in DMEM containing 10% FBS and
either 5 or 0.5 nM C225.2/PFOT490A,L491V. For competi-
tion experiments, incubation was performed with 20 nM
p19-E18/siRNA complexes, 5 nM C225.2/PFOT490A,L491V
and varying concentrations (0–4 M) of SUMO-E18 in
complete media. Cells were transfected for 6 h, followed
by incubation in fresh, complete media for an additional
18 h. Following trypsinization and neutralization (PBSA,
2% FBS), cells were analyzed on a BD LSR II HTS cy-
tometer (BDBiosciences). Background fromA431 cells was
subtracted from all measurements, which were then nor-
malized to that of untreated cells (when p19/siRNA or
C225.2/PFOT490A,L491V was used alone) or cells treated with
the corresponding concentration of C225.2/PFOT490A,L491V
only (all other cases). Cell viability was measured im-
mediately prior to analyzing GFP expression using the
WST-1 reagent (Roche) as previously described (11). Back-
ground subtracted values were normalized to that of
C225.2/PFOT490A,L491V-treated cells.
PLK1 silencing assays
Transfection procedures for PLK1 were identical to those
described above for GFP with the following exceptions.
A431 cells were seeded at a density of 45 000 cells/well
in 48-well plates for measuring knockdown of PLK1
mRNA; 18 000 cells/well in 96-well plates for measur-
ing knockdown of PLK1 protein and 12 000 cells/well
in 96-well plates for measuring cell viability. P19-E18 and
p19N15K,G16R-E18 were complexed with negative control
siRNA (Thermo Fisher Scientific) or PLK1 siRNA (GE
Dharmacon), and incubated with cells in the presence of
5 nM C225.2/PFOT490A,L491V. Expression levels of PLK1
mRNA and protein were measured after 24 h by qPCR and
western blot respectively, as described below. Cell viabil-
ity was measured after 48 hours using the WST-1 reagent
(Roche) following manufacturer’s instructions. All values
were normalized to that of control cells treated with 5 nM
C225.2/PFOT490A,L491V only.
qPCR
RNAextractionwas performed using theNucleoSpinRNA
kit (Clontech) according to manufacturer’s instructions.
RT-PCRand amplificationwere performed using theQuan-
tiTect SYBR Green RT-PCR kit (Qiagen) according to
manufacturer’s instructions on a Roche Lightcycler 480
(Roche). -actin was used as the housekeeping gene. Primer
sequences are listed below. Data were analyzed using the
comparative CT method.
PLK1 forward: 5′-CACCAGCACGTCGTAGGATTC -
3′
PLK1 reverse: 5′-CCGTAGGTAGTATCGGGCCTC-
3′
-actin forward: 5′-GTCTGCCTTGGTAGTGGATA
ATG-3′
-actin reverse: 5′-TCGAGGACGCCCTATCATGG-3′
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Western blot
Cells were incubated in lysis buffer (1× LDS sample buffer
(Thermo Fisher Scientific) containing 0.1 M DTT (Am-
resco), Benzonase (1:3000; Sigma) and protease inhibitors
(Roche)) for 20 min at 4◦C with shaking, followed by man-
ual scraping. Following SDS-PAGE, proteins were trans-
ferred to a nitrocellulose membrane using the iBlot Dry
Blotting System (Thermo Fisher Scientific) and blocked
for 1 h in TBST containing 5% non-fat milk. Incubation
was performed with mouse anti-PLK1 (1:100, clone F8,
Santa Cruz Biotechnology) at 4◦C overnight and HRP-
conjugated donkey anti-mouse IgG (1:3000, BioLegend)
for one hour at room temperature. Signal was developed
using SuperSignal West Pico chemiluminescent substrate
(Thermo Fisher Scientific). Antibodies were then stripped
using Restore western blot stripping buffer (Thermo Fisher
Scientific) and the membrane was re-probed using mouse
anti--actin (1:15 000, clone AC15, Thermo Fisher Scien-
tific). Band intensities were quantified using ImageJ.
Uptake assays
A431-d2EGFP cells were seeded at a density of 15 000
cells/well in 96-well plates 16–20 h prior to the experiment.
The p19-E18 constructs were incubated with fluorescently
labeled siRNA (Seq I) at a 1:1 molar ratio for 30 min at
4◦C. The p19-E18/siRNA complexes were then diluted in
DMEMcontaining 10%FBS at varying concentrations and
incubated with cells for 0–6 h in a reverse timecourse. For
competition experiments, incubation was performed with
20 nM of p19-E18/siRNA complexes and varying concen-
trations (0–4 M) of SUMO-E18 in complete media. Af-
ter 6 h, cells were washed with PBS, trypsinized, neutral-
ized with cold PBSA containing 2% FBS and analyzed
on an iQue Screener (IntelliCyt). All liquid handling was
performed using an EL406 plate washer (BioTek) and a
Freedom EVO 150 liquid handling system (Tecan) to mini-
mize variability. Background from untreated cells were sub-
tracted from all measurements, which were then converted
to number of fluorophores using QuantumAlexa Fluor 647
MESF beads following manufacturer’s instructions (Bangs
Laboratories).
Model construction
A mathematical model of ordinary differential equations
(ODE) (Supplementary Figure S1) was developed describ-
ing the trafficking of the siRNA–carrier complex through
extracellular, endosomal and cytoplasmic compartments.
Multiple species were monitored due to the modular nature
of binding (Supplementary Table S2). A net internalization
model was employed for receptor-mediated uptake. The
siRNA carrier was implemented as a monovalent binder to
the receptor for simplification using apparent affinity val-
ues. Endosomal release was modeled as a first-order pro-
cess, the rate of which was fitted from linking the uptake
and silencing data of p19-E18.RNA interferencewas imple-
mented using a simplifiedmodel adapted fromBartlett et al.
(23) (Supplementary Figures S2–S4). Parameters were ob-
tained from the literature or measured experimentally un-
less stated otherwise (Supplementary Tables S3 and S4). For
validation, the model was confirmed to faithfully predict
the silencing behavior of the higher affinity p19-E18 clones
(SupplementaryFigure S5). All simulationswere performed
using MATLAB (MathWorks). A detailed description and
rationale of the mathematical model is provided in Supple-
mentary Data (Supplementary Figures S3–S5).
RESULTS
Engineering and characterization of high-affinity p19 clones
To develop p19 into a monodisperse siRNA carrier, we
first mutated its solvent-exposed cysteines to non-reactive
residues to prevent uncontrolled crosslinking. Wild-type
p19 contains three free cysteines, two of which are ex-
posed to solvent (C134, C160) and one embedded within
the core (C110). Introducing the C134S and C160A sub-
stitutions (24) eliminated multimerization and yielded a
monomeric peak when analyzed by size-exclusion chro-
matography (SEC) (Figure 1A). The clone p19C134S,C160A is
herein referred to as ‘p19’.
Next, we increased the affinity of p19 using yeast sur-
face display, a well-established technique for directed evolu-
tion. A library of p19 clones was generated by error-prone
PCR and displayed on the surface of yeast. The resulting
yeast library was subject to multiple rounds of kinetic selec-
tions performed at 37◦C in 55% mouse serum, to enrich for
tighter binders under experimental conditions that mimic
an in vivo environment. The siRNA antigens used for selec-
tions were rotated between three different sequences (Seq
F, Seq I and Cy5-labeled AllStars negative control siRNA)
to prevent affinity maturation towards a specific sequence.
Two out of the three siRNAs contained 2′OMe modifica-
tions at select positions (Seq F and Seq I).
Sequence analysis of the enriched library revealed con-
vergence to a single clone, p19G16R,D47N (19 out of the 20
clones analyzed). The remaining clone outside of this fam-
ily contained the mutations N15K and I123V. Interestingly,
N15K andG16R are in close proximity to the siRNA back-
bone (Figure 1B), suggesting that the positively charged side
chains of Lys and Arg may interact with phosphates on the
siRNA backbone. D47N is in an unstructured loop that is
not involved in binding, and I123V is at the dimerization
interface. To analyze the contribution of each mutation to-
wards binding affinity or protein stability, p19 clones con-
taining different combinations of the aforementioned mu-
tations were expressed solubly. The D47N mutation was
found to affect neither soluble expression levels nor bind-
ing affinities, and I123V had a destabilizing effect (data not
shown). Thus, clones containing either of these mutations
were not pursued further.
The p19 clones selected for further analysis contained the
substitutions N15K and G16R, individually or in combi-
nation (Figure 1C). All three expressed well with compara-
ble yields to p19 (Supplementary Figure S6). TheA260/A280
ratios of the clones following his-tag purification were be-
tween 0.8 and 1.3, indicating that contaminating nucleic
acids may be bound to the proteins non-specifically. Anion
exchange chromatography (AEX) reduced theA260/A280 ra-
tios to between 0.59 and 0.64, effectively stripping away the
fugitive nucleic acids. Following purification, all p19 clones
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Figure 1. Affinity-matured p19 clones display high affinity and stability. (A) SEC analysis of the p19 clones. Thirty g of each protein was analyzed in
PBS at 1 mg/ml. (B) Model structure of p19N15K,G16R. The highlighted substitutions were introduced into the crystal structure of wild-type p19 (1RPU)
using PyMOL. The two monomers forming the homodimer are shown in different shades. (C) Sequences of the p19 clones used in this study. Variations
from the wild-type sequence are highlighted. (D) Affinity measurements using biolayer interferometry (BLI) and soluble equilibrium titrations using MSD
technology (MSD-SET). Shown for each method are the averages of two measurements. The results from each method were averaged to calculate the
overall fold-improvement in affinity.
eluted as monomeric peaks from SEC without evidence of
aggregation, suggesting high stability (Figure 1A).
Finally, the binding affinities of the p19 clones were ana-
lyzed using two orthogonal techniques: BioLayer Interfer-
ometry (BLI), and a soluble equilibrium titration method
utilizing MSD technology (MSD-SET) (Figure 1D). The
same siRNA antigen (Seq 7) was used for both analyses
to maintain uniformity between assays, which contained
2′OMe modifications at select positions. The affinity of p19
measured by both methods closely matched values reported
in the literature for wild-type p19 (13,25–27), suggesting
that binding was not significantly affected by the removal
of surface cysteines (as expected) or the modification of se-
lect 2′ hydroxyls. P19 engages the 2′ hydroxyls at certain
positions (12,13), but the remaining network of contacts
made with phosphate groups and the end-capping interac-
tions made at the siRNA termini likely maintain binding.
Measurements made by both methods showed a consistent
trend where p19N15K,G16R had the highest affinity, followed
by p19G16R, p19N15K and p19. Overall, we successfully cre-
ated a series of p19 clones with multiple-fold improvements
in affinity, up to 160-fold for the tightest binder.
Development and characterization of targeted, high affinity
siRNA carriers
To use the p19-based siRNA carrier in combination with
our PFO-based endosome-disrupting agent, which was tar-
geted to EGFR via the antibody Cetuximab (C225), we cre-
ated two sets of p19 constructs fused to different EGFR
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binders (Figure 2A). The p19 clones were targeted to the
same receptor as the endosome-disrupting agent to maxi-
mize the overlap of siRNA and PFO in endosomal com-
partments. For the same reason, we chose binders that were
confirmed not to compete with C225 for receptor binding.
Two separate siRNA carriers were created by genetically
linking p19 to two different EGFR binders, which speak to
themodularity of the design where p19 can be readily linked
with a targetingmoiety of choice. The first binder was based
on a modified Sso7d scaffold, termed ‘E18’ herein (origi-
nally clone E18.6 (20), and the second binder was based on
the fibronectin (Fn3) scaffold, termed ‘E6’ herein (originally
clone E6.2.6 (28)). Fusing E6 to the C terminus of p19 al-
lowed slightly better silencing compared to its N-terminal
counterpart, and thus only C-terminal fusions were consid-
ered for further analysis (data not shown). All carrier con-
structs were pure (Supplementary Figure S7) and eluted as
monomeric peaks from SEC (Supplementary Figure S8),
which suggested that they were stable and unaggregated.
Next, we characterized the EGFR affinities and size dis-
tributions of the carriers following siRNA loading, to con-
firm that they behave as monodisperse carriers targeting
the receptor. Theoretically, the p19 homodimer is capable
of binding only one molecule of siRNA at a time, due its
caliper-like mode of binding that caps each siRNA termini
(13). Thus, we expected that siRNA-induced aggregation
was unlikely.
First, the binding affinities of p19-E6 and p19-E18
against EGFR were measured by Biolayer Interferometry
(BLI), where a 1:1 binding model was used to obtain ap-
parent affinity values. The analysis was performed at pH
7.4, mimicking extracellular pH, and pH 5.5, mimicking en-
dosomal pH. SiRNA was loaded onto the carriers by mix-
ing at a 1:1 molar ratio (p19-E6/E18 dimer: siRNA) at high
concentrations (M range) to drive loading. Interestingly,
complexation with siRNA slightly increased the affinities to
EGFR (Figure 2B). This may be due to the siRNA provid-
ing further stabilization of the p19-E6/E18 dimer, which is
expected to have higher affinities than the monomer due to
avidity effects. Binding to EGFR was independent of pH
for both carriers, regardless of whether they were loaded
with siRNA. P19-E6 and p19-E18 had similar affinities for
EGFR,making them functionally equivalent constructs de-
spite being structurally distinct.
Next, we analyzed the size distribution of the targeted
carriers by Dynamic Light Scattering (DLS) before and af-
ter siRNA loading (Figure 2C). All p19 clones were tested
to discern whether the addition of positive charge in the
affinity-matured mutants affected potential tendencies for
aggregation. The measured diameters of the carrier/siRNA
complexes did not significantly differ from those of the un-
loaded carrier, and were roughly equal to the length of the
p19 homodimer (6 nm) or siRNA (7 nm). Polydispersitywas
constant or slightly higher following siRNA loading, which
may be due to the dynamic association and dissociation of
siRNA. However, a high polydispersity was expected over-
all as p19 and the EGFR binder is connected by a flexible
peptide linker that can adopt multiple conformations.
We further confirmed that the p19 clones and siRNA
form monomeric complexes by SEC (Supplementary Fig-
ure S9). Fluorescently labeled siRNA (Seq I) was used for
this purpose, to distinguish the siRNA component from the
protein component via the dye. The labeled siRNA did not
contain any free dye at detectable levels. At both pH 7.4 and
pH 5.5, the siRNA eluted together with p19 in amonomeric
peak. A small fraction of dissociated siRNAwas detected in
the starting p19/siRNA complex but gradually disappeared
in the affinity-matured p19/siRNA complexes, consistent
with the relative binding affinities that were measured. In-
terestingly, we observed signs of instability with free p19
(without siRNA) at pH 5.5, which were completely absent
with the siRNA-bound counterparts at the same pH. This
supported the earlier notion that binding to siRNA may
further stabilize the p19 dimer.
Overall, our results suggested that the targeted carrier
constructs form uniform complexes with siRNA and can
subsequently engage EGFR with high affinity.
Higher carrier affinity against siRNA correlates with more
potent in vitro silencing
Next, we compared the silencing potency of the differ-
ent high-affinity carriers in combination with a PFO-
based endosome-disrupting agent that was previously re-
ported (C225.2/PFOT490A,L491V) (17). Silencing was mea-
sured in A431 cells stably transfected with destabilized
EGFP (A431-d2EGFP cells) (11). siRNA was loaded onto
the carriers as before by mixing, and the endosome-
disrupting agent was prepared as described (17).
In contrast to a previously reported system where a
p19 construct targeted to the ephrin receptor EphA2 en-
abled silencing by itself (29), p19-E6/siRNA and p19-
E18/siRNA complexes alone did not affect GFP expres-
sion in the absence of C225.2/PFOT490A,L491V (Supplemen-
tary Figure S10a). This may be due to the targeting of dif-
ferent receptors, whose internalization pathways and in-
tracellular fates may differ. In contrast, the PFO-based
endosome-disrupting agent when used alone did cause a
dose-dependent reduction in GFP expression. The target-
ing antibodyC225.2 by itself (without PFOT490A,L491V) reca-
pitulated this phenomenon, suggesting that C225.2 was re-
sponsible for the suppression rather than pore formation by
PFOT490A,L491V (Supplementary Figure S10B). We specu-
late that C225-mediated blockage of EGF growth signaling
may affect the expression of GFP from the CMV promoter,
which has been reported to be activated by the MEKK1–
JNK pathway (30) downstream of EGF (31). To control for
this C225.2-mediated effect, GFP expression levels in cells
treated with both siRNA and the PFO-based endosome-
disrupting agent were normalized to that of cells treated
with the latter only.
Transfection was performed for 6 h in complete media,
after which the media was replaced for an overnight in-
cubation. Potent silencing was observed only when cells
were treated with both agents (Figure 3A and B). In addi-
tion, silencing was not accompanied with any signs of cy-
totoxicity (Figure 3C). To strictly compare the effects of
siRNA–carrier affinity on silencing potency, the concen-
tration of the endosome-disrupting agent was kept con-
stant to fix the efficiency of endosomal release. The degree
of silencing was concentration-dependent on both siRNA
and C225.2/PFOT490A,L491V, demonstrating that each per-
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Figure 2. Characterization of EGFR-targeted p19 clones. (A) Model structures of the targeted p19 constructs used in this study. Left: E18, an EGFR
binder engineered on a modified sso7d scaffold (1SSO) (20), was fused to the C terminus of p19 separated by a (G4S)3 linker. Right: E6, an EGFR binder
engineered on the Fn3 scaffold (1TTG) (28), was fused to the C terminus of p19 separated by a (G4S)3 linker. (B) EGFR affinities of the targeted p19
constructs measured by biolayer interferometry (BLI). Analysis was performed with either empty or siRNA-loaded constructs in citrate-phosphate buffer.
Shown are the averages of two independent measurements. (C) Size distribution of empty or siRNA-loaded p19 constructs measured by dynamic light
scattering (DLS). All samples were analyzed at 5 M in PBS. Shown are the averages of two independent measurements.
formed orthogonal roles that were both necessary. Silencing
was not observed when negative-control siRNA was used
(Supplementary Figure S10C). No significant differences
in potency were observed whether E6 or E18 was used as
the targeting moiety, consistent with the notion that they
are functionally equivalent. Interestingly, we observed that
stronger siRNA-carrier affinity consistently led to more po-
tent silencing, with the most potent system achieving an
EC50 of 230 pM for silencing of GFP. Such a potency
in vitro is higher than commercial lipofectamine (Supple-
mentary Figure S10d) and among the highest reported for
protein-based siRNA delivery methods (32). Furthermore,
the complete lack of cytotoxicity created a therapeutic win-
dow spanning multiple orders of magnitude.
Removing the targeting moiety from the p19 carriers
decreased the silencing efficacy up to 1000-fold (Figure
3D), demonstrating that EGFR-mediated internalization
was essential for high potency. This result was expected,
as we have previously shown that C225.2/PFOT490A,L491V
predominantly permeablizes endosomal membranes fol-
lowing EGFR-mediated internalization (17). Thus, deliv-
ery of siRNA is maximal when it can co-localize with
PFOT490A,L491V in endosomes most efficiently. The untar-
geted p19/siRNA complexes were likely taken up by non-
specific pinocytosis, an inefficient method for both internal-
izing into cells and co-localizing into PFO-containing en-
dosomes. At the high concentration ranges where silencing
was observed, the potency was independent of affinity. This
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Figure 3. Potent, affinity-dependent silencing mediated by the targeted siRNA carriers. A431-d2EGFP cells were transfected with p19 carriers loaded with
GFP siRNA. The concentration of C225.2/PFOT490A,L491V was fixed at either 5 or 0.5 nM. Transfection was performed for 6 h, and GFP expression
or cell viability was measured at 24 h. The collected data were normalized to that of control cells treated only with the corresponding concentration of
C225.2/PFOT490A,L491V. (A) Transfection using p19-E18 carriers. Shown is the average of three independent measurements. Normalized data was fitted to
a four-parameter logistic curve to obtain the EC50 of silencing. (B) Identical experiment to (A) but with p19-E6 carriers. (C) Cell viability was measured
using the WST-1 reagent following the transfection procedures of (A) and (B). (D) Identical experiment to (A) but with untargeted p19 carriers. Shown is
the average of two independent measurements.
was likely because all p19 clones were fully associated with
siRNA at concentrations significantly higher than their KD
values.
Finally, we investigated whether the positive correlation
between siRNA-carrier affinity and silencing potency ob-
served with GFP extends also to endogenous genes. To this
end, we chose Polo-like kinase 1 (PLK1) as a model target,
which is involved in cell division and overexpressed inmulti-
ple tumor types (33). As our delivery system targets EGFR,
a validated cancer marker (34), silencing of targets that can
potentially synergize with EGFR inhibition is a possible ap-
plication to be explored. As with GFP, p19N15K,G16R-E18
produced stronger silencing of PLK1 at both theRNA (Fig-
ure 4A) and protein level (Figure 4B) at both concentrations
tested, 24 h after transfection. The functional effects of si-
lencing were determined at a gross level by measuring the
viability of the culture at 48 h after transfection. Consistent
with the relative degrees of silencing, cell viabilitywas signif-
icantly lower when p19N15K,G16R-E18 was used (Figure 4C).
Although p19-E18 did reduce expression of PLK1 it did not
affect cell viability, suggesting that either the degree or du-
ration of silencing was insufficient to cause a functional dif-
ference.
Overall, the siRNA carriers enabled potent silencing of
gene expression in a manner dependent on binding to both
siRNA and EGFR.
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Figure 4. Silencing of endogenous PLK1 is affinity dependent. A431 cells were transfected with p19-E18 or p19-E18N15K,G16R that were loaded with either
PLK1 siRNA or negative control (NEG) siRNA. The concentration of C225.2/PFOT490A,L491V was fixed at 5 nM. After 24 h, expression levels of PLK1
(relative to -actin) were quantified by qPCR for mRNA (A) or by western blot for protein (B). A representative blot is shown below. (C) Cell viability at 48
h after transfection was measured using theWST-1 reagent. All measurements were normalized to that of control cells treated with C225.2/PFOT490A,L491V
only. Shown are the averages of three independent experiments ± S.E.M. for each panel. *P< 0.05, ***P< 0.001, ****P< 0.0001 determined by two-way
ANOVA with Dunnett’s post- test.
siRNA-carrier affinitymodulates the intracellular pharmaco-
dynamics of siRNA
We hypothesized that the higher affinity carriers achieved
greater silencing because they internalized siRNA more ef-
ficiently. Lower affinity carriers have a higher probability
of losing their cargo before it can be taken up by receptor-
mediated endocytosis. Subsequently, wemeasured the num-
ber of siRNA molecules taken up into A431-d2EGFP cells
by each p19-E18 clone using fluorescently-labeled siRNA
(Seq I). Our methodology was confirmed to measure inter-
nal, but not surface-bound siRNA (Supplementary Figure
S11). As expected, higher affinity generally correlated with
greater internalization at all concentrations tested (Figure
5A). Uptake eventually saturated with p19G16R-E18 and
p19N15K,G16R-E18, indicating that the internalization limit
set by the kinetic properties of the targeting moiety (E18)
and receptor (EGFR) were reached. Interestingly, although
p19N15K,G16R-E18 had consistently produced more potent
silencing compared to p19G16R-E18 (Figure 3A and B), the
number of siRNAs internalized by these carriers were iden-
tical over time. This discrepancy suggested that the stronger
affinity of p19N15K,G16R may be affecting a step in the deliv-
ery process downstream of cellular uptake.
To further probe this observation, we titrated the num-
ber of siRNAs being internalized into cells by p19-E18 and
p19N15K,G16R-E18 and compared the corresponding degrees
of silencing. To equalize the number of siRNA and carri-
ers that are taken up, the carrier/siRNA complexes were
fixed at a high concentration (20 nM) while a competitor
for receptor binding was introduced at increasing concen-
trations. E18 fused to a SUMO tag (SUMO-E18) was used
as the competitor. A large molar excess of SUMO-E18 was
required to compete with the p19-E18 carriers, as the bind-
ing interaction of the former ismonovalent and the latter bi-
valent.With this setup, both p19-E18 and p19N15K,G16R-E18
internalized decreasing numbers of siRNA with increas-
ing concentrations of SUMO-E18 (Supplementary Fig-
ure S12A), confirming that the carrier/siRNA complexes
were taken up specifically via EGFR. Interestingly, un-
der the same setup but with the addition of a fixed con-
centration of the PFO-based endosome-disrupting agent,
p19-E18/siRNA displayed a gradual decrease in silencing,
whereas silencing by p19N15K,G16R-E18 was largely unaf-
fected (Supplementary Figure S12B). Plotting the number
of internalized siRNA and the corresponding expression
levels of GFP highlights that the per-siRNA potency of si-
lencing is higher when siRNA is delivered by the higher
affinity carrier (Figure 5B), even when similar numbers of
siRNA are taken up into the cell.
This result initially appeared counterintuitive, as once
the siRNA/carrier complex is internalized, stronger bind-
ing between the two is expected to hamper siRNAdischarge
and subsequent loading onto RISC. Furthermore, it raised
the question of whether and how far siRNA–carrier affin-
ity could be increased for additional improvements in ef-
ficacy. To address these questions, we built a mathemati-
cal model of our delivery system and simulated silencing at
varying affinities (Figure 6). Briefly, we first created a simpli-
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Figure 5. Higher carrier affinity for siRNA improves both uptake into the cell and the downstream efficiency of delivery within the cell. (A) The time-
and concentration-dependent uptake of siRNA into. A431-d2EGFP cells mediated by each p19-E18 clone. Denoted concentrations are those of the p19-
E18/siRNA complex. The p19-E18 clones were loaded with fluorescently labeled siRNA (Seq I), and the background-subtracted fluorescence in cells was
converted to number of siRNAs using calibration beads. Shown are the averages of two independentmeasurements. (B) The silencing potencies mediated by
p19-E18 and p19N15K,G16R-E18 per internalized siRNA. A soluble competitor for EGFR (sumo-E18) was used to titrate the number of siRNA complexes
that are internalized. Fluorescently labeled siRNA (Seq I) was used to measure siRNA uptake after 6 h, and GFP siRNA was used to measure GFP
knockdown in an analogous setting (Supplementary Figure S12). Shown are the averages of three independent measurements.
Figure 6. Mathematical modeling predicts the existence of an affinity optimum that maximizes silencing. (A) Schematic of mathematical model. Mass
action kinetics was used to describe the delivery of siRNA between extracellular, endosomal and cytoplasmic compartments. The concentrations of free
siRNA, free carrier and the siRNA-carrier complex were tracked separately in each compartment. Ø indicates degradation. (B) The predicted dependence
of silencing potency on the dissociation rate between siRNA and its carrier. All other parameters were held constant, including the rate of endosomal
release and the initial extracellular concentration of siRNA.
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fied model for RNA interference using data in the literature
correlating the number of cytoplasmic siRNA and silenc-
ing (Supplementary Figure S2). Next, the uptake of p19-
E18/siRNA complexes was incorporated using a receptor
net-internalization model (Supplementary Figure S3). Fi-
nally, a first-order rate of endosomal release was determined
using the uptake and silencing data of p19-E18 (Supplemen-
tary Figure S4). The resulting model was validated by pre-
dicting the silencing behavior of the higher affinity carriers
(Supplementary Figure S5).
To simplify model simulations, the affinity of the car-
rier was varied by fixing the on-rate at 1 × 105 M−1 s−1, a
standard estimate for biomolecular interactions, and vary-
ing the off-rate only. The modeling results predict that af-
ter an initial gain, continually increasing the siRNA-carrier
binding strength would indeed eventually decrease silenc-
ing (Figure 6b). This simulation suggests the existence of
an affinity optimum thatmaximizes silencing when all other
parameters are equal. The eventual decrease in silencing is
predicted to stem from siRNA sequestration by p19 (Sup-
plementary Figure S13), mirroring the natural function of
p19 as a viral inhibitor of RNA interference in the infected
host (35).
Overall, our experimental observations and modeling re-
sults suggest that tighter binding between siRNA and its
carrier may improve the cellular uptake and intracellular
pharmacodynamics of siRNA, but that this trendwould not
continue indefinitely. As such, we posit that there exists an
optimal affinity that maximizes the efficiency of delivery via
RNA binding proteins, and propose that this may also hold
true for other non-covalent delivery materials.
DISCUSSION
In this study, we have reported the engineering of ultra-
high affinity siRNA binders based on the viral protein p19,
which contained the substitutions N15K and G16R that
likely engage backbone phosphates. As targeted siRNA car-
riers, these high affinity p19 clones improved the potency of
silencing up to 20-fold, yielding a notably effective system.
This improvement was partially due to increased cellular
uptake, and also to more efficient delivery to RISC follow-
ing siRNA internalization. Indeed, higher potencies were
achieved when siRNA was loaded onto the higher affinity
carrier, even when equal numbers were internalized.
Our experimental findings were unexpected, as high affin-
ity in the intracellular space has generally been deemed un-
desirable for delivery systems relying on non-covalent pack-
aging of siRNA, in some cases motivating the development
of vehicles that decrease affinity in response to environmen-
tal cues within the cell (36). In the cytoplasm, inefficient dis-
sociation of the siRNA complex can prevent the release of
free siRNA for loading onto RISC. In the endosome, in-
efficient dissociation may hinder the endosomal escape of
siRNA (37). Although the exactmechanisms underlying en-
dosomal escape are not clearly understood formost delivery
systems, it is also conceivable that the endosome-disrupting
component itself requires liberation, necessitating the deliv-
ery particle to dissociate globally. Consequently, with deliv-
ery systems that are packaged into a single entity in partic-
ular, siRNA–carrier binding strength may be coupled with
other parameters in a manner that renders it challenging to
investigate independently.
When the affinity-dependence of silencing potency was
characterized unambiguously in our delivery system, three
separate affinity regimes were identified. In the first regime,
low affinity limited the efficient uptake of siRNA, as siRNA
and its targeted carrier could not remain stably associated.
Thus, increasing the affinity in this regime led to more ef-
ficient uptake of siRNA and subsequently more efficient
silencing. In the second regime, affinity no longer limited
uptake, which was now saturated, but increasing affinity
again led to better silencing. In the third regime, siRNA
discharge was predicted to become limiting, and increas-
ing affinity correlated with a decreased efficiency of silenc-
ing. Our results mirror the experimental observations made
with a polyplex delivery system, where increasingly stronger
siRNA-polymer binding correlated with an increase in si-
lencing potency followed by an eventual decline in vitro
and in vivo (16). Future studies will be required to vali-
date the experimental and theoretical concepts of affinity-
dependence in different models of siRNA delivery.
The exact mechanism of how tighter siRNA-carrier as-
sociation improves siRNA potency without increasing up-
take also requires further investigation. It is unlikely that
the efficiency of endosomal escape was altered in our ex-
perimental setup, as the endosome-disrupting functional-
ity was provided by a physically separate agent. Also, the
pores formed by PFO are 25–30 nm in diameter (38), which
are in theory sufficiently large to allow the passage of an
entire p19–siRNA complex approximately 8 nm in diame-
ter (Figure 2C). It is possible that siRNA was better pro-
tected against intracellular nucleases, either in endolysoso-
mal compartments or the cytoplasm. In particular, while
slower unpackaging in the cytoplasm can penalize potency
by hindering the release of free siRNA, slower unpackaging
in endosomes presents no obvious penalty based on the de-
sign of our delivery system. Being able to maintain a higher
concentration of intact siRNA for a prolonged period of
time in endocytic compartments may conceivably increase
the probability of successful escape events.
Multiple improvements reported in this study increase
the feasibility of this delivery system functioning in vivo.
Biophysically, p19s are resistant to siRNA-induced aggre-
gation and capable of high affinity binding to siRNA con-
taining chemically modified 2′ hydroxyls. Practically, the
targeted p19 carriers can be expressed, purified and loaded
with siRNA in a straightforward manner that is amenable
to large-scale production. Functionally, the ultra-high affin-
ity p19 clones are expected to improve the stability of the
siRNA-carrier complex during circulation, providing better
protection and targeting capabilities. In addition, the excep-
tional in vitro potency of the delivery system suggests that
silencing can be achieved with reasonable doses of siRNA.
Finally, the two-component system developed here is sim-
pler than our previously reported system of three compo-
nents (11), and supported by successful precedents of in vivo
co-injection strategies. For example, the Dynamic Polycon-
jugate systems where targeted siRNA (cholesterol-siRNA)
was co-administered with co-targeted endosome-disrupting
agents (PBAVE-based polymers (39) or melittin-like pep-
tides (40)) achieved efficient silencing in the liver. The non-
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particulate nature of our delivery system, in combination
with its modularity to swap in binders against different tar-
gets, can potentially allow efficient targeting of other inter-
nal organs or tumors.
Lastly, outside of siRNA delivery, the ultra-high affin-
ity p19 clones reported here may also serve as useful tools
for various other biological applications. For example, wild-
type p19 has already been used to isolate miRNA or siRNA
from biological samples (41–50); inhibit RNAi in plants to
enhance yields of recombinant proteins (51–53); or inhibit
RNAi in mammalian cells to enhance titers of recombinant
adenovirus (54). Rauschhuber et al. also demonstrated in
vivo utility by inhibiting RNAi in a tissue-specific manner
(54). Additionally, p19 has been used to stabilize siRNAs
in bacteria for recombinant production of siRNA in E. coli
(55). As these implementations all depend on tight binding
to siRNA, the ultra-high affinity p19 clones reported here
are expected to further enhance application performance
and utility.
SUPPLEMENTARY DATA
Supplementary Data are available at NAR Online.
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